UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Stock Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 4.5% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 785,878 shares of the company's stock after purchasing an additional 33,978 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.96% of IDEXX Laboratories worth $324,913,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. Norges Bank purchased a new stake in IDEXX Laboratories in the 4th quarter valued at $412,258,000. Flossbach Von Storch SE raised its position in IDEXX Laboratories by 5,439.3% in the 4th quarter. Flossbach Von Storch SE now owns 473,336 shares of the company's stock valued at $195,696,000 after purchasing an additional 464,791 shares during the last quarter. Alyeska Investment Group L.P. purchased a new stake in IDEXX Laboratories in the 4th quarter valued at $156,412,000. William Blair Investment Management LLC raised its position in IDEXX Laboratories by 701.6% in the 4th quarter. William Blair Investment Management LLC now owns 422,133 shares of the company's stock valued at $174,527,000 after purchasing an additional 369,471 shares during the last quarter. Finally, BNP Paribas Financial Markets raised its position in IDEXX Laboratories by 221.3% in the 4th quarter. BNP Paribas Financial Markets now owns 441,319 shares of the company's stock valued at $182,459,000 after purchasing an additional 303,966 shares during the last quarter. Hedge funds and other institutional investors own 87.84% of the company's stock.

Wall Street Analyst Weigh In

IDXX has been the subject of several research reports. Wall Street Zen upgraded shares of IDEXX Laboratories from a "hold" rating to a "buy" rating in a research report on Thursday. Morgan Stanley lifted their target price on IDEXX Laboratories from $548.00 to $558.00 and gave the company an "overweight" rating in a research note on Monday, May 5th. Bank of America lifted their target price on IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a research note on Tuesday, February 4th. Stifel Nicolaus lifted their target price on IDEXX Laboratories from $460.00 to $510.00 and gave the company a "hold" rating in a research note on Monday, May 19th. Finally, Piper Sandler lifted their target price on IDEXX Laboratories from $435.00 to $510.00 and gave the company a "neutral" rating in a research note on Monday, February 10th. Three research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, IDEXX Laboratories has a consensus rating of "Moderate Buy" and a consensus price target of $536.00.

Insiders Place Their Bets

In other IDEXX Laboratories news, Director M Anne Szostak sold 1,046 shares of the business's stock in a transaction on Wednesday, May 21st. The shares were sold at an average price of $513.74, for a total transaction of $537,372.04. Following the sale, the director now directly owns 262 shares in the company, valued at approximately $134,599.88. The trade was a 79.97% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.98% of the company's stock.

IDEXX Laboratories Stock Performance

NASDAQ IDXX traded down $3.26 during trading hours on Friday, hitting $501.57. 443,606 shares of the stock were exchanged, compared to its average volume of 651,454. The company has a market cap of $40.34 billion, a price-to-earnings ratio of 47.01, a price-to-earnings-growth ratio of 3.41 and a beta of 1.52. IDEXX Laboratories, Inc. has a 12-month low of $356.14 and a 12-month high of $530.60. The stock has a 50-day moving average of $440.69 and a 200 day moving average of $434.53. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its earnings results on Thursday, May 1st. The company reported $2.96 EPS for the quarter, topping the consensus estimate of $2.93 by $0.03. The company had revenue of $998.43 million for the quarter, compared to analyst estimates of $998.25 million. IDEXX Laboratories had a net margin of 22.78% and a return on equity of 55.82%. The business's revenue was up 3.6% on a year-over-year basis. During the same period in the previous year, the firm earned $2.71 EPS. As a group, equities research analysts forecast that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.